AVITA Medical, Inc. — Form 8-K Summary
Business Context and Reporting Period
AVITA Medical, Inc. filed a current report on March 1, 2021 regarding events occurring February 24, 2021. The filing concerns a marketed public offering of common stock under the company’s existing Form S-3 shelf registration statement. No quarterly or annual financial results are reported.
Offering and Key Financial Information
| Item | Details |
|---|---|
| Firm shares | 2,795,000 authorized but unissued common shares |
| Public offering price | $21.50 per share |
| Gross proceeds from firm shares | Approximately $60.1 million, before underwriting discounts, commissions, and offering expenses |
| Underwriter option | 30-day option for an additional 419,250 shares |
| Maximum additional gross proceeds | Approximately $9.0 million, before offering costs, if the option is fully exercised |
| Closing | The offering, including all option shares, closed on March 1, 2021 |
| Potential total shares sold | 3,214,250 shares |
| Potential total gross proceeds | Approximately $69.1 million, before underwriting discounts, commissions, and offering expenses |
The filing does not provide updated revenue, profit, cash flow, margins, debt, cash balance, liquidity, or share-count information after the offering.
Material Changes Versus the Prior Comparable Period
The filing does not present a prior-period comparison. The material transaction disclosed is the issuance of new common stock, which increases shares outstanding and provides additional equity capital. The filing text does not state the net proceeds or the specific use of proceeds.
Outlook, Risks, Contingencies, and Unusual Items
- The transaction was conducted pursuant to a prospectus supplement dated February 25, 2021 and the accompanying October 16, 2020 base prospectus under Form S-3 registration statement No. 333-238680.
- Piper Sandler & Co. and Cowen and Company, LLC acted as book-running managers.
- AVITA agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or reimburse certain required payments.
- The filing includes customary securities-law restrictions stating that the offering is not an offer or solicitation where unlawful absent applicable registration or qualification.
Important Facts for Investors to Verify
- Confirm the final prospectus and underwriting agreement, including underwriting discounts, commissions, expenses, and net proceeds.
- Verify the number of shares issued and the resulting diluted shares outstanding after the March 1, 2021 closing.
- Review management’s stated use of proceeds in the prospectus materials, as it is not specified in the filing text.
- Assess the effect of the equity issuance on dilution, liquidity, and the company’s funding runway using subsequent financial filings.